Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)

• DOI: 10.1007/s40257-024-00853-4
• Publication Date: 2024-03-25T18:02:15Z
• Authors: Jonathan I. Silve...; Melinda J. Gooderham; Amy S. Paller; Mette Deleuran; Christopher G. Bu...; Linda F. Stein Gold; DirkJan Hijnen; Brian M. Calimlim; Wan-Ju Lee; Henrique D. Teixeira; Xiaofei Hu; Shiyu Zhang; Yang Yang; Ayman Grada; Andrew M. Platt; Diamant Thaçi
• Keywords: Clinical Global Impression; SCORAD

Atopic dermatitis is a chronic inflammatory disease characterized by increased itch, skin pain, poor sleep quality, and other symptoms that negatively affect patient quality of life. Upadacitinib, an oral selective Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine 2, approved to treat moderate-to-severe atopic dermatitis. We aimed evaluate the effect upadacitinib on patient-reported outcomes over 52 weeks in adults adolescents Data from two phase III monotherapy trials (Measure Up 1, NCT03569293; Measure NCT03607422) were integrated. Changes pruritus, symptoms, sleep, life, mental health, impression evaluated. Patient-reported outcome assessments included Worst Pruritus Numerical Rating Scale, Patient-Oriented Eczema Measure, Dermatology Life Quality Index, Dermatitis Symptom Impact Hospital Anxiety Depression SCORing index, Patient Global Impression Severity, Change, Treatment. Minimal clinically important differences, achievement scores representing minimal burden, change baseline evaluated patients who received through week placebo 16. This analysis 1609 (upadacitinib 15 mg, N = 557; 30 567; placebo, 485). Baseline demographics characteristics generally similar across all arms. The proportion treated reporting improvements itch rapidly steadily 8, was sustained 52. Patients receiving also experienced pain which continued 16; maintained reports improved 32, quality-of-life By both groups rapid emotional state, 12, achieved meaningful anxiety depression. Improvements health 32 mg earlier those mg. Through 16, versus assessed outcomes. Adults once-daily early ClinicalTrials.gov identifiers NCT03569293 (13 August 2018) NCT03607422 (27 July 2018). dermatitis, eczema, condition causes painful itchy dry skin, burdensome has negative impact These frequently lead disruption daily activities such as school work, decreased self-confidence, social isolation, anxiety, depression, disturbance. Symptoms disturbance, can only be patients. Therefore, it consider patients' perceptions their related especially when evaluating treatment benefits. Upadacitinib orally administered drug In clinical 1 2), we investigated how (15-mg 30-mg dose) given once would life 1-year period. measured changes time skin-related activities, overall within first 1–2 treatment. increase following lasted year conclusion, led lasting well-being